

Translational Research for HCC

Pei-Jer Chen

Professor, National Taiwan University

The new development for HCC has made significant progress. In addition to many molecular target therapies, the immune checkpoints therapy appeared to be a promising one. Oncolytic virotherapy was also under clinical trials, and even to be in combination with immunotherapy. For the TCAE, despite the lack of success in combination with MTTs, there are new explorations using additional metabolic blockade. Early clinical trials are undertaken. Finally, the challenging aspects for adjuvant therapies after curative treatment of early HCC will be reviewed. The recently comprehensive investigations about the genetic mutations profiles for HCC also point out new direction for future chemo-prevention of HCC.